# International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

> **NCT05593770** · PHASE2,PHASE3 · TERMINATED · sponsor: **NEAT ID Foundation** · enrollment: 28 (actual)

## Conditions studied

- COVID-19
- SARS-CoV2 Infection
- Coronavirus Infection

## Interventions

- **DRUG:** Fostamatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05593770
- **Lead sponsor:** NEAT ID Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-27
- **Primary completion:** 2023-12-14
- **Final completion:** 2023-12-14
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Following a meeting of the DSMB on 20th September 2023, the recommendation was made to the sponsor on 26th September 2023 that the Fostamatinib arm of the trial ceases enrolment and study medication is discontinued immediately.
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593770, "International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05593770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*